Back to resultsEvaluation of Clinical Efficacy of Pentoxifylline on Patients With Glomerulonephritis
Primary Purpose
Primary Glomerulonephritis
Status
Completed
Phase
Not Applicable
Locations
Taiwan
Study Type
Interventional
Intervention
pentoxifylline
Sponsored by
About this trial
This is an interventional treatment trial for Primary Glomerulonephritis focused on measuring glomerulonephritis
Eligibility Criteria
Inclusion Criteria: glomerular diseases with subnephrotic proteinuria Exclusion Criteria: DM, hepatitis, systemic immunologic renal diseases
Sites / Locations
- Yung-Ming Chen
Outcomes
Primary Outcome Measures
proteinuria
Secondary Outcome Measures
inflammatory mediators
Full Information
NCT ID
NCT00154661
First Posted
September 8, 2005
Last Updated
September 8, 2005
Sponsor
National Taiwan University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT00154661
Brief Title
Evaluation of Clinical Efficacy of Pentoxifylline on Patients With Glomerulonephritis
Official Title
Evaluation of Clinical Efficacy of Pentoxifylline on Patients With Glomerulonephritis
Study Type
Interventional
2. Study Status
Record Verification Date
June 2001
Overall Recruitment Status
Completed
Study Start Date
January 2000 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
June 2001 (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
National Taiwan University Hospital
4. Oversight
5. Study Description
Brief Summary
we hypothesize that PTX might be effective in lowering proteinuria by modulating renal MCP-1 production in human glomerulonephritis.
Detailed Description
Pentoxifylline (PTX) is a phosphodiesterase inhibitor that is widely used for the treatment of peripheral vascular occlusive disorders. In addition, PTX has shown its ability to attenuate nephrotic syndrome secondary to membranous glomerulonephritis and lupus nephritis, and to reduce subnephrotic proteinuria due to early and advanced diabetic nephropathy. However, data with respect to its effect on non-nephrotic primary glomerular diseases are lacking. Moreover, while the anti-proteinuric effect of PTX has been largely attributed to down-regulation of TNF-a, it remains unknown whether other mediators, especially MCP-1, are also affected by PTX. Because our previous works have shown that PTX attenuates proteinuria and suppresses renal MCP-1 mRNA expression in experimental glomerulonephritis in rats, we hypothesize that PTX might be effective in lowering proteinuria by modulating renal MCP-1 production in human glomerulonephritis. This study was thereby conducted to investigate the potential anti-proteinuric and anti-MCP-1 effects of PTX in subnephrotic patients with primary glomerular diseases.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Primary Glomerulonephritis
Keywords
glomerulonephritis
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
20 (false)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
pentoxifylline
Primary Outcome Measure Information:
Title
proteinuria
Secondary Outcome Measure Information:
Title
inflammatory mediators
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
glomerular diseases with subnephrotic proteinuria
Exclusion Criteria:
DM, hepatitis, systemic immunologic renal diseases
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pan-Chyr Yang
Organizational Affiliation
Professor and vice-Dean
Official's Role
Study Chair
Facility Information:
Facility Name
Yung-Ming Chen
City
Taipei
ZIP/Postal Code
100
Country
Taiwan
12. IPD Sharing Statement
Learn more about this trial
Evaluation of Clinical Efficacy of Pentoxifylline on Patients With Glomerulonephritis
We'll reach out to this number within 24 hrs